Damon Silvestry
Net Worth

Last updated:

What is Damon Silvestry net worth?

The estimated net worth of Mr. Damon Silvestry is at least $2,483,225 as of 16 Dec 2020. He owns shares worth $174,675 as insider and has received compensation worth at least $2,308,550 in Biora Therapeutics, Inc..

What is the salary of Damon Silvestry?

Mr. Damon Silvestry salary is $461,710 per year as Chief Operating Officer in Biora Therapeutics, Inc..

How old is Damon Silvestry?

Mr. Damon Silvestry is 56 years old, born in 1969.

What stocks does Damon Silvestry currently own?

As insider, Mr. Damon Silvestry owns shares in one company:

Company Title Shares Price per share Total value
Biora Therapeutics, Inc. (PROG) Chief Operating Officer 197,484 $0.88 $174,675

What does Biora Therapeutics, Inc. do?

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Damon Silvestry insider trading

Biora Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 58,081 $4.55 $264,269
Purchase
Common Stock 58,081 $4.55 $264,269
Purchase
Common Stock 63,870 N/A N/A

Biora Therapeutics key executives

Biora Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Mr. Damon Silvestry (56) Chief Operating Officer
  • Mr. Eric d'Esparbes (57) Chief Financial Officer